- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00629642
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)
August 31, 2017 updated by: Astellas Pharma Inc
A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
A clinical study to compare the efficacy and safety of solifenacin succinate in patients with neurogenic detrusor overactivity.
In this randomized, double blind, double dummy study solifenacin will be compared to placebo and an active comparator, oxybutynin hydrochloride.
Patients will be randomized to one of four treatment arms; solifenacin 10mg, solifenacin 5mg, placebo or oxybutynin 15mg.
Patients will be assessed over a four week treatment period.
Study Type
Interventional
Enrollment (Actual)
249
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brisbane, Australia
-
Melbourne, Australia
-
Perth, Australia
-
Randwick, Australia
-
-
-
-
-
Antwerpen, Belgium
-
Esneux, Belgium
-
Fraiture-en-Condroz, Belgium
-
Gent, Belgium
-
Leuven, Belgium
-
Melsbroek, Belgium
-
-
-
-
-
Brno, Czechia
-
Ceske Budejovice, Czechia
-
Prague, Czechia
-
-
-
-
-
Caen, France
-
Garches, France
-
Paris, France
-
Ploemeur, France
-
-
-
-
-
Berlin, Germany
-
Hagenow, Germany
-
Heidelberg, Germany
-
Kiel, Germany
-
-
-
-
-
Nyiregyhaza, Hungary
-
Sopron, Hungary
-
Szeged, Hungary
-
-
-
-
-
Firenze, Italy
-
Milan, Italy
-
Rome, Italy
-
Torino, Italy
-
-
-
-
-
Apeldoorn, Netherlands
-
Eindhoven, Netherlands
-
Nijmegen, Netherlands
-
-
-
-
-
St. Petersburg, Russian Federation, 196084
-
St. Petersburg, Russian Federation, 190089
-
-
-
-
-
La Coruna, Spain
-
-
Alicante
-
San Juan de Alicante, Alicante, Spain
-
-
Barcelona
-
Badalona, Barcelona, Spain
-
-
Madrid
-
Getafe, Madrid, Spain
-
-
-
-
-
Cardiff, United Kingdom
-
Newcastle Upon Tyne, United Kingdom
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent has been obtained
Subjects with neurogenic detrusor overactivity due to:
- Multiple sclerosis(MS)(EDSS≤8) or
- Spinal cord injury(SCI)(partial or complete lesions)
- MS or SCI symptoms should be stable for >= 6 months
- Neurogenic detrusor overactivity symptoms should be stable for >= 6 months
- Subject is willing and able to perform clean, intermittent, catheterization, if required
- Subject is willing and able to take study medication in compliance with the protocol
Exclusion Criteria:
- Subjects with neurogenic detrusor overactivity due to Parkinson's or cerebrovascular disease
- Subjects with Sjögren's Syndrome or any similar symptoms
- Subjects with evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs
- Subjects with stress incontinence or mixed incontinence where stress is the predominant factor as determined by the investigator
- Subjects with evidence of pressure sores >= grade 2
- Subjects with a history of bladder sphincterotomy
- Subjects with known history of vesico-ureteral reflux without upper urinary tract infection
- Any clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study or includes a history of acute urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony), severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, narrow angle glaucoma or shallow anterior chamber
- Subjects undergoing hemodialysis
- Subjects with severe hepatic impairment
- Concurrent use of drugs intended to treat symptoms of overactive bladder
- Use of antidepressants or muscle relaxants which have not been administered at a constant dose for >= 3 months
- Use of non-drug treatment intended to treat overactive bladder symptoms including electrostimulation therapy, botulinum toxin and vanilloids therapy in the six months prior to the commencement of the study
- Use of permanent, indwelling catheters
- Known or suspected hypersensitivity to solifenacin succinate, oxybutynin hydrochloride, other anti cholinergics or lactose
- Concomitant use of a strong CYP3A4 inhibitor, e.g. ketoconazole
- Pregnant women, women who intend to become pregnant during the study, women of childbearing potential who are sexually active and practicing an unreliable method of birth control or women who will be lactating during the study. Reliable contraceptive methods are intra-uterine devices, contraceptive pills of combination type, hormonal implants and injectable contraceptives
- Participation in any clinical study within 30 days of randomization, or the limit set by national law, whichever is longer
- Employees of the Astellas Group, third parties associated with the study, or the study site
- Subjects with maximum bladder capacity >= 400ml at visit 2
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I.Solifenacin succinate 10mg (2x5mg 1/day)
Oral
|
Oral, 10mg
Other Names:
Oral, 5mg
Other Names:
|
Experimental: II.Solifenacin succinate 5mg (5mg 1/day)
Oral
|
Oral, 10mg
Other Names:
Oral, 5mg
Other Names:
|
Active Comparator: III.Oxybutynin hydrochloride 15mg (5mg 3/day)
Oral
|
Oral, 15mg
|
Placebo Comparator: IV. Placebo
Oral
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in maximum cystometric capacity
Time Frame: 4 Weeks
|
4 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in bladder volume at first involuntary contraction
Time Frame: 4 Weeks
|
4 Weeks
|
Change from baseline in pressure at first leak
Time Frame: 4 Weeks
|
4 Weeks
|
Change from baseline in volume at first leak
Time Frame: 4 Weeks
|
4 Weeks
|
Change from baseline in maximum detrusor pressure
Time Frame: 4 Weeks
|
4 Weeks
|
Change from baseline in micturition or catheterization frequency
Time Frame: 4 Weeks
|
4 Weeks
|
Change from baseline in incontinence episodes
Time Frame: 4 Weeks
|
4 Weeks
|
Incidence and severity of adverse events
Time Frame: 4 Weeks
|
4 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Department of (Neuro) Urology, Universitaire Ziekenhuizen KU Leuven
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2008
Primary Completion (Actual)
January 28, 2011
Study Completion (Actual)
January 28, 2011
Study Registration Dates
First Submitted
February 26, 2008
First Submitted That Met QC Criteria
February 27, 2008
First Posted (Estimate)
March 6, 2008
Study Record Updates
Last Update Posted (Actual)
September 1, 2017
Last Update Submitted That Met QC Criteria
August 31, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Urologic Diseases
- Urinary Bladder Diseases
- Neurologic Manifestations
- Multiple Sclerosis
- Sclerosis
- Spinal Cord Diseases
- Urinary Bladder, Neurogenic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Oxybutynin
- Solifenacin Succinate
Other Study ID Numbers
- 905-EC-005
- 2006-005523-42 (Other Identifier: EudraCT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States